Before the diagnosis of LM, ten patients had undergone systemic therapy with EGFR-tyrosine kinase inhibitor (TKI) or pemetrexed, and the patient with ALK rearrangement had undergone treatment with systemic ALK inhibitor and bevacizumab (Table 1). Here, ALK is linked to lymphangioma.